Non-steroidal Anti-inflammatory Treatment in Cancer Cachexia: a Systematic Literature Review
Overview
Affiliations
Background: There are no established treatments for cachexia. Recently it has been suggested that the evidence for non-steroidal anti-inflammatory (NSAID) treatment is sufficient to support its regular clinical use. Primary objective in this systematic review was to assess efficacy and safety of NSAID treatment in improving body weight and muscle mass in patients with cancer cachexia. Secondary objectives were to assess whether this treatment could improve other cachexia domains such as anorexia and food intake, catabolic drive and function.
Material And Methods: A systematic literature review of PubMed, EMBASE and Cochrane Central register of controlled trials database was carried out using both text words and MeSH/EMTREE terms.
Results: Thirteen studies were included; all but two trials showed either improvement or stabilization in weight or lean body mass. Seven studies were without a comparator. Studies are generally small and a few are methodologically flawed, often due to multiple outcomes with excess risk of false positives.
Conclusion: NSAIDs may improve weight in cancer patients with cachexia, and there is some evidence on effect on physical performance, self-reported quality of life and inflammatory parameters. Evidence is too frail to recommend NSAID for cachexia outside clinical trials. This is supported by the known side effects of NSAIDs, even though the reviewed literature report almost negligible toxicity.
Understanding cachexia and its impact on lung cancer and beyond.
Yue M, Qin Z, Hu L, Ji H Chin Med J Pulm Crit Care Med. 2024; 2(2):95-105.
PMID: 39169934 PMC: 11332896. DOI: 10.1016/j.pccm.2024.02.003.
SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023).
Soria Rivas A, Escobar Alvarez Y, Blasco Cordellat A, Majem Tarruella M, Molina Mata K, Motilla de la Camara M Clin Transl Oncol. 2024; 26(11):2866-2876.
PMID: 38822976 PMC: 11466990. DOI: 10.1007/s12094-024-03502-8.
Updates in Cancer Cachexia: Clinical Management and Pharmacologic Interventions.
Pandey S, Bradley L, Del Fabbro E Cancers (Basel). 2024; 16(9).
PMID: 38730648 PMC: 11083841. DOI: 10.3390/cancers16091696.
Advancing cancer cachexia diagnosis with -omics technology and exercise as molecular medicine.
Hesketh S Sports Med Health Sci. 2024; 6(1):1-15.
PMID: 38463663 PMC: 10918365. DOI: 10.1016/j.smhs.2024.01.006.
R-ketorolac ameliorates cancer-associated cachexia and prolongs survival of tumour-bearing mice.
Chrysostomou S, Eder S, Pototschnig I, Mayer A, Derler M, Mussbacher M J Cachexia Sarcopenia Muscle. 2024; 15(2):562-574.
PMID: 38302863 PMC: 10995265. DOI: 10.1002/jcsm.13422.